Literature DB >> 1381795

The molecular basis of cardiovascular hypertrophy: the role of the renin-angiotensin system.

M Paul1, D Ganten.   

Abstract

Factors that can influence cardiovascular growth are becoming increasingly important for our understanding of such complex diseases as cardiac hypertrophy, coronary artery disease, atherosclerosis, and hypertension. Several proto-oncogenes were found to be involved in the regulation of abnormal cell growth in cardiovascular disease. It is also evident that some peptide hormones, which are well known to be involved in blood pressure control, may play a role as growth modulators. Angiotensin II is one such peptide. It elevates blood pressure through its direct vasoconstrictor, sympathomimetic, and (through release of aldosterone) sodium-retaining activity but also appears to have mitogenic actions. Interestingly, all components of the renin-angiotensin system were found locally in cardiovascular tissues. The question remains whether angiotensin can act directly as a growth factor or whether it does so indirectly by influencing or modulating cell growth factors. A better understanding of the renin-angiotensin system as a direct or indirect mediator for cardiovascular hypertrophy would offer new and interesting insights into the pathophysiology of hypertension and possibly novel options for the treatment of cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381795

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

1.  Differential effects of thyroid hormone on renin secretion, content, and mRNA in juxtaglomerular cells.

Authors:  A Ichihara; H Kobori; Y Miyashita; M Hayashi; T Saruta
Journal:  Am J Physiol       Date:  1998-02

2.  Mitochondrial aldehyde dehydrogenase prevents ROS-induced vascular contraction in angiotensin-II hypertensive mice.

Authors:  Hyehun Choi; Rita C Tostes; R Clinton Webb
Journal:  J Am Soc Hypertens       Date:  2011-04-01

3.  Impact of Antihypertensive Drug Class on Outcomes in SPRINT.

Authors:  Douglas D DeCarolis; Amy Gravely; Christine M Olney; Areef Ishani
Journal:  Hypertension       Date:  2022-03-09       Impact factor: 9.897

4.  Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme.

Authors:  R Morishita; G H Gibbons; K E Ellison; W Lee; L Zhang; H Yu; Y Kaneda; T Ogihara; V J Dzau
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

5.  Long-term effects of brief antihypertensive treatment on systolic blood pressure and vascular reactivity in young genetically hypertensive rats.

Authors:  O Traub; M C Lloyd; R C Webb
Journal:  Cardiovasc Drugs Ther       Date:  1995-06       Impact factor: 3.727

Review 6.  Ventricular dysrhythmias, left ventricular hypertrophy, and sudden death.

Authors:  F H Messerli; F Soria
Journal:  Cardiovasc Drugs Ther       Date:  1994-08       Impact factor: 3.727

7.  The association between growth patterns and blood pressure in children and adolescents: A cross-sectional study of seven provinces in China.

Authors:  Manman Chen; Ying Ma; Tao Ma; Yanhui Li; Di Gao; Li Chen; Jieyu Liu; Yi Zhang; Jun Jiang; Xinxin Wang; Yanhui Dong; Jun Ma
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-11-30       Impact factor: 3.738

Review 8.  Peripheral artery disease: potential role of ACE-inhibitor therapy.

Authors:  Giuseppe Coppola; Giuseppe Romano; Egle Corrado; Rosa Maria Grisanti; Salvatore Novo
Journal:  Vasc Health Risk Manag       Date:  2008

9.  Metabolic and cardiovascular risk in patients with a history of differentiated thyroid carcinoma: A case-controlled cohort study.

Authors:  Massimo Giusti; Lorenzo Mortara; Roberta Degrandi; Francesca Cecoli; Michele Mussap; Guido Rodriguez; Diego Ferone; Francesco Minuto
Journal:  Thyroid Res       Date:  2008-09-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.